Sponsors (22)
The bill aims to secure and speed access to medical goods and strengthen supply‑chain resilience—benefiting hospitals, patients, and certain U.S. manufacturers—at the cost of higher prices for some purchasers, potential fiscal and diplomatic consequences, and risks to regulatory safeguards and data/privacy protections.
Hospitals, clinics, and patients (including those with chronic conditions) would get more reliable access to medical devices, medicines, and supplies because the bill diversifies suppliers, expands manufacturing capacity, and expedites cross‑border movement and authorizations.
Taxpayers and the nation would face lower strategic vulnerability because reducing dependence on a few foreign suppliers strengthens national security and resilience to export controls or foreign-policy disruptions.
U.S. manufacturers, small businesses, and workers could gain from more domestic or nearer‑shore production, clearer identification of trusted partners, and expanded access to foreign procurement markets, supporting job creation and export opportunities.
Hospitals, health systems, and patients could face higher costs if procurement shifts toward more 'trusted' or nearer‑shore suppliers and stronger IP protection raises prices for medicines and devices.
Taxpayers could face increased fiscal pressure from reduced tariff revenue, possible subsidies or support for reshoring, and added administrative costs tied to new processes and reviews.
U.S. firms, consumers, and hospitals risk retaliation or broader trade disruptions if partners are deprioritized or if enforcement and suspension of benefits prompt countermeasures from trading partners.
Based on analysis of 7 sections of legislative text.
Authorizes the President to negotiate "trusted trade partner" agreements to reduce trade barriers for medical goods, with congressional notice, review, and monitoring requirements.
Official title: To authorize the President to enter into trade agreements for the reciprocal elimination of duties or other import restrictions with respect to medical goods to contribute to the national security and public health of the United States, and for other purposes.
Introduced March 18, 2025 by Nicole Malliotakis · Last progress March 18, 2025
Creates a legal framework authorizing the President to negotiate "trusted trade partner" agreements with foreign countries to remove or reduce duties and other trade barriers for medical goods, and to foster supply diversification, regulatory cooperation, and research collaboration to strengthen U.S. medical supply chains. Requires advance notice to Congress, detailed reporting, advisory committee and ITC input, a multi-step congressional review and disapproval process before agreements take effect, and monitoring with remedial actions for partner noncompliance.